Malene Brondberg
Director/Board Member bij PHOTOCURE ASA
Vermogen: 3 185 $ op 31-03-2024
Profiel
Malene Brondberg is currently a Director at Photocure ASA. She was previously the Head of Global Research at ABG Sundal Collier Holding ASA and the Global Head of Research at ABG Sundal Collier ASA. From 2018 to 2023, she served as the Chief Executive and Financial Officer at Nordic Nanovector ASA. Ms. Brondberg holds a graduate degree and an MBA from the University of Aalborg.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
THOR MEDICAL ASA
0.01% | 31-12-2022 | 32 000 ( 0.01% ) | 3 185 $ | 31-03-2024 |
Actieve functies van Malene Brondberg
| Bedrijven | Functie | Begin |
|---|---|---|
| PHOTOCURE ASA | Director/Board Member | - |
Eerdere bekende functies van Malene Brondberg
| Bedrijven | Functie | Einde |
|---|---|---|
| THOR MEDICAL | Chief Executive Officer | 01-02-2023 |
ABG Sundal Collier ASA
 ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The private company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Director of Research - Equity | - |
| ABG SUNDAL COLLIER HOLDING ASA | Corporate Officer/Principal | - |
Opleiding van Malene Brondberg
| University of Aalborg | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ABG SUNDAL COLLIER HOLDING ASA | Finance |
| PHOTOCURE ASA | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ABG Sundal Collier ASA
ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The private company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Finance |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
